MarketPulse

bezuclastinib

2 articles
BenzingaBenzinga··Vandana Singh

Cogent Biosciences Stock Surges on FDA Acceptance of Bezuclastinib Application

$COGT surges 5.24% after FDA accepts bezuclastinib NDA for Non-Advanced Systemic Mastocytosis, with decision expected by December 2026.
COGTFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cogent Biosciences Presents Expanded SUMMIT Trial Results for Bezuclastinib at 2026 AAAAI Meeting

Cogent Biosciences presented expanded SUMMIT trial data showing bezuclastinib achieved significant symptom reduction and tryptase normalization in systemic mastocytosis patients, supporting its FDA regulatory applications.
COGTdisease modificationclinical results